<?xml version='1.0' encoding='utf-8'?>
<document id="23594709"><sentence text="Microsomal transfer protein inhibition in humans." /><sentence text="Microsomal triglyceride transfer protein (MTP) is a key protein in the secretion of apolipoprotein B-containing lipoproteins"><entity charOffset="11-23" id="DDI-PubMed.23594709.s2.e0" text="triglyceride" /></sentence><sentence text=" Its pharmacological inhibition is associated with a decrease in LDL cholesterol (LDL-C) and triglycerides"><entity charOffset="69-80" id="DDI-PubMed.23594709.s3.e0" text="cholesterol" /><entity charOffset="82-87" id="DDI-PubMed.23594709.s3.e1" text="LDL-C" /><entity charOffset="93-106" id="DDI-PubMed.23594709.s3.e2" text="triglycerides" /><pair ddi="false" e1="DDI-PubMed.23594709.s3.e0" e2="DDI-PubMed.23594709.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23594709.s3.e0" e2="DDI-PubMed.23594709.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23594709.s3.e0" e2="DDI-PubMed.23594709.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23594709.s3.e1" e2="DDI-PubMed.23594709.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23594709.s3.e1" e2="DDI-PubMed.23594709.s3.e2" /></sentence><sentence text=" However, the clinical use of MTP inhibitors has been uncertain because of the gastrointestinal adverse events and the increase in liver fat content observed during their administration" /><sentence text="" /><sentence text="Lomitapide, a systemic MTP inhibitor, significantly reduces LDL-C in homozygous familial hypercholesterolemia (hoFH) when administered concurrently with other lipid-lowering therapies, including apheresis"><entity charOffset="0-10" id="DDI-PubMed.23594709.s6.e0" text="Lomitapide" /><entity charOffset="60-69" id="DDI-PubMed.23594709.s6.e1" text="LDL-C" /><pair ddi="false" e1="DDI-PubMed.23594709.s6.e0" e2="DDI-PubMed.23594709.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23594709.s6.e0" e2="DDI-PubMed.23594709.s6.e1" /></sentence><sentence text=" Its lipid-lowering effect is additive to that of existing drugs" /><sentence text=" In the presence of an up-titration regiment and low-fat diet, lomitapide is generally well tolerated and liver fat accumulation stabilizes after the initial increase"><entity charOffset="63-73" id="DDI-PubMed.23594709.s8.e0" text="lomitapide" /></sentence><sentence text=" Elevation of alanine aminotranferase levels greater than 3 times the upper limit of normal can be managed successfully with temporary dose reduction"><entity charOffset="14-21" id="DDI-PubMed.23594709.s9.e0" text="alanine" /></sentence><sentence text=" Drug-drug interaction studies show that concomitant treatment of lomitapide with other lipid-lowering drugs is generally safe"><entity charOffset="66-76" id="DDI-PubMed.23594709.s10.e0" text="lomitapide" /></sentence><sentence text=" Based on these findings, lomitapide was recently approved for the treatment of hoFH as add-on therapy"><entity charOffset="26-36" id="DDI-PubMed.23594709.s11.e0" text="lomitapide" /></sentence><sentence text="" /><sentence text="MTP inhibition is a valuable therapeutic approach for hoFH" /><sentence text=" Long-term safety consequences of liver fat accumulation will need to be assessed" /><sentence text="" /></document>